1. Patenting Antibodies
The Past, Present, and Future
Timothy J. Shea, Jr.
Director
Sterne, Kessler, Goldstein & Fox
P.L.L.C.
3rd Annual Antibody Therapeutics
Conference
IBC Life Sciences
San Diego, CA
December 6, 2005

2. Why patent antibodies?
• Therapeutic antibodies have come
of age!
– 18 mAbs approved by FDA to date
– approximately 350 in clinical trials
– $10B in revenues in 2004
– Six mAbs → global revenues > $500M
– Market expected to grow by 20% per
year over next 5 years
– $30B market by 2010
– Better toxicity profiles/ faster approval
2

3. Why patent antibodies?
• Competition is increasing
• Strong patent position is essential
– protect R&D investment
– maximize value of technology to potential
investors and partners
• Currently no mechanism for generic
versions of biologics (i.e., biosimilars)
– Even if generic competitors allowed, will
likely face high barrier to entry
– Potential for de facto extension of exclusivity
3

4. Patent Law Fundamentals
• Antibodies are patentable subject
matter
– Products of nature, including living things,
are patentable subject matter. (Diamond v.
Chakrabarty (S. Ct. 1980))
– Patentable subject matter includes “anything
under the sun that is made by man.”
• Ab patents must distinguish over
products occurring in nature
– Examples: mAbs, chimeric/humanized Abs,
Fc mutants
4

5. Patent Law Fundamentals
• Antibodies must meet same standards
for patentability as other inventions
• Antibody must be novel
– Not disclosed in single prior art ref.
• Antibody must be nonobvious
– Cannot be obvious modification of
what was is already known in art
• Application must describe antibody with
sufficient specificity
– serves notice function
– fixes patent rights
5

6. Patent Law Fundamentals
• Application must enable how to
make and use antibody
– Standard = one of ordinary skill in
relevant art
– No need to teach what is well-known
• Application must describe best
mode for practicing invention
– Known to inventor at time of filing
– No duty to update
6

7. Patenting Antibodies – The Cases
• The case law has evolved as antibody
technology has evolved
• The cases tend to lag the technology
• Many of cases today deal with technologies first
developed 10 or more years ago
• Early cases – hybridoma technology and
immunoassays (mid-1970s)
• More recent cases – technologies for
making chimeric, humanized, and human
antibodies (early-mid 1980s)
7

8. Early Cases
• In re Strahilevitz (C.C.P.A. 1982)
– Claims: method for removing a hapten (e.g.
drug) or antigen from blood using an
immunodialysis process
• Claims not limited to specific haptens/antibodies
– Facts: Application lacked specific examples;
no human treatment data, no dialysis or
adsorption data
– Issue: Did application enable claims?
– Held: claims enabled
• Preparing antibodies to specific antigens
and haptens was well known in art
• Selection of matrix, dialysis membrane
and flow rate for dialysis well known.
8

9. Early Cases
• Hybritech Inc. v. Monoclonal Antibodies, Inc.
(Fed. Cir. 1986)
– Claims: Sandwich assay utilizing mAbs with
affinity of at least 108 liters/mole
– Issue: Were claims invalid as obvious?
– Facts: Prior Art:
• method of making mAbs (Kohler & Milstein), use
of mAbs to map epitopes, high affinity antibodies,
and “predicted” use of mAbs in immunoassays
– Held: Not obvious
• prior art was “invitation to experiment” only
• Commercial success of Hybritech kits was
evidence of nonobvious
9

10. Early Cases
• In re Wands (Fed. Cir. 1988)
– Claims: Immunoassay for detection of HBsAg using
high-affinity IgM mAbs (covered any IgM mAb)
– Facts:
• Applicants had deposited a single cell line
• Exr. Had rejected for lack of enablement
– Issue: Were claims enabled?
– Held: enabled
• Deposit not necessary if cell lines obtainable from
readily available sources/materials
• Preparing/screening hybridomas was well known in art
• Need for some experimentation is OK, as long as
not undue
• Wands factors: look at (1) quantity of experimentation,
(2) amount of direction or guidance,(3) working
examples, (4)nature of invention, (5)state of art, (6)
relative skill in art, (7) predictability of art, (8) breadth of
claims
10

11. Early Cases
• Johns Hopkins Univ. v. Cellpro, Inc. (Fed. Cir. 1998)
– Claims : Purified suspensions of stem cells and mAbs used to
produce the suspensions
– Facts:
• Civin had discovered My-10 antigen expressed on immature
stem cells, but not mature cells; claimed anti-My-10 mAbs
• CellPro produced similar suspension with antibody to CD34
• My-10 and CD34 recognized by OSA as same antigen
– Issues: Did CellPro infringe? Claims enabled?
– Held: CellPro infringed and claims enabled
• Court construed claims to cover all antibodies that bind CD34
• Fact that CellPro mAbs bound different epitope on CD34
irrelevant
• Using methods taught, one skilled in the art could make many
more anti-CD34 mAbs w/out undue experminentation
11

12. Recent Cases
• Noelle v. Lederman (Fed. Cir. April 2004)
– Interference Proceeding
• Where application/application or application/patent claim same
patentable invention
• Proceeding to determine first to invent
– Claimed Technology:
• Antibodies to CD40CR antigen found on T cells
• antibody blocks binding of antigen to CD40 receptor on B cells
and prevents B cell activation
– Facts:
• Noelle had claims to genus of any CD40CR mAb, as well as
the murine, chimeric, humanized and human forms of the mAb
• Noelle application only disclosed murine CD40CR antigen
– No disclosure of human antigen or any other CD40
antigen other than murine
– Issue: Did application adequately describe claimed subject
matter?
12

13. Recent Cases
• Noelle v. Lederman, con’t.
– To prevail in interference, Noelle had to
show claimed subject matter was described
in earliest applications
– Held: Priority application supported claims
to mouse mAbs, but not to genus and human
CD40CR mAbs
• Can broadly claim antibody by binding affinity for
antigen, but only if application discloses a “fully
characterized antigen”
• Noelle did not describe human CD40CR antigen
(e.g. by structure, formula, chemical name, etc.)
• Disclosure of single mouse antigen, not enough to
support claim to genus
– Needed to disclose more species to claim genus
13

14. Recent Cases
• Chiron Corp. v. Genentech, Inc. (Fed. Cir. June 2004)
– Claims: Monoclonal antibodies that bind to human HER2 antigen
– Facts:
• Chiron sued Genentech alleging Herceptin infringed Chiron patent
• `561 patent claims: “A monoclonal antibody that binds to human c-erbB-2 antigen.
(Genus)
• `561 patent claimed priority to applications filed in 1984, 1985, and 1986 (to prevail
Chiron had to show priority appls. Supported claims
• 1984 application – one murine mAb that binds HER2; produced by hybridoma
method
– Hybridoma deposited but appl. does not identify antigen by structure,
function, etc.
• 1985 application – six more murine mAbs; hybridomas for all; antigen identified by
mol. wt.
– No mention of chimeric or humanized but says mAb not limited by source or
manner made
• 1986 application – six more murine mAbs; three hybridomas deposited
– No mention of chimeric or humanized but says mAb not limited by source or
manner made
14

15. Recent Cases
• Chiron Corp. v. Genentech, Inc. con’t.
– Issue: Whether priority applications supported (i.e.,
described and enabled) later claimed subject matter?
– Held: No support – claims invalid
• Ct. found `561 claim covered chimeric
and humanized mAbs as well as mouse
• Appl. specifically stated invention not
limited to source of mAb or how made
• Patent need not enable later-arising
technology
15

16. Recent Cases
• Chiron Corp. v. Genentech, Inc. con’t
– Nascent technology requires “specific and
useful” teaching to enable
– 1984 appl. – no need to enable
chimeric/humanized mAbs, but did not
describe
– 1985 appl. – no specific/useful teaching of
chimeric or humanized → not enabled
– 1986 appl. - no specific/useful teaching of
chimeric or humanized → not enabled
– Follow-on applications need to be updated
16

17. Current Issues – Freedom-to-Operate
• Right to Exclude ≠ Right to Make
– A patent does not give patent owner right to
do anything
• Only right to exclude others from practicing patent
– A patent can be subordinate to a broader,
dominant patent (e.g., genus vs. species)
– Holder of subordinate patent may need
license to practice its own technology
– Must compare claims of dominant patent
(not disclosure) to what your company is
doing or plans to do (e.g., make, use, sell)
17

18. Current Issues – Freedom-to-Operate
• “The Monoclonal Maze”
– www.signalsmag.com
– Antibody Production
• Cabilly patent (Genentech)
– Est. $220M in royalties in 2005
– Currently in reexamination proceedings
– Humanization Technology
• Winter patents (MRC)
• Queen Patents (PDL)
– Transgenic Mice
• Medarex, Abgenix
– Phage/Ribosome/Yeast Display
• CAT, Morphosys, Dyax, Xoma, etc.
18

19. Current Issues – Freedom-to-Operate
19

20. Current Issues – Freedom-to-Operate
20

21. Current Issues – Freedom-to-Operate
• 35 U.S.C. § 271(e)(1) – FDA Safe Harbor
– Scope broadened by Supreme Court
See Merck KGaA v. Integra Life
Sciences (2005)
– Impact on research tools remains
unclear
• Case on remand
• Offshoring
– 35 U.S.C. § 271(g) –importation of product made
abroad by process patented in U.S. is an
infringing act
– But See Bayer v. Housey (Fed. Cir. 2003)
• Only extends to importation of products, not data
(screening data?)
21

22. The Future of Antibody Patenting
• Antibody technology will continue to
evolve creating new patenting
opportunities
– Increased potency
• Fc engineering
• Glycosylation engineering
• Antibody conjugates
– New treatment modalities
• scFv, linked fragments, minibodies, diabodies,
triabodies, etc.
– New targets
– Manufacturing alternatives
• Plant cells ?
• High-throughput screening?
22

23. The Future of Antibody Patenting
• Continuing efforts to design around
dominating patents
• Patent expirations
• Less dependence on older technologies
• Biosimilars?
– Coming, but not sure when or what will look
like
23

24. Patenting Antibodies
Thank You
Timothy J. Shea, Jr.
Director
Sterne, Kessler, Goldstein & Fox, P.L.L.C.
(202) 772-8679
tshea@skgf.com
24